Preliminary estimation of a new urea-mineral preparation in feeding young fattening cattle

Новый мочевино-минеральный препарат производится, в первую очередь, из отечественных сырвевых материалов, т.е. из доломитов (карбонат кальция и магния) и фосфорной кислоты производимой из апатитов, с прибавкой некоторых минеральных элементов и мочевины. Этот препарат содержит м.пр. свыше 55% мочевины, 4% Р, 3,5% Са и 3,7% Na. Испытания препарата проводились в 1983 г. на 48 бычках низинной черно-пестрой породы, разделенных на 3 группы по 16 животных в группе. Животных кормили индивидуально. На основании полученных результатов испытаний можно формулировать следующие заключения: - применение нового мочевино-минерального препарата дало результаты продукции сходные с препаратом „Валчан”, - использование азота мочевины из нового препарата не было лучше, чем препарата „Валчан” и кристаллической мочевины, - новый мочевино-минеральный препарат характеризуется тем преимуществом, что может изготовляться почти исключительно из отчечественных сырьевых материалов. Однако, следует проводить дальнейшие испытания по кормлению, которые бы позволили получить более подробную информацию касающуюся качества указанного препарата.New urea-mineral preparation is produced, first of all, from home raw materials, i.e. from dolomites (calcium and magnesium carbonate) and phosphoric acid produced from apatites, with addizion of some mineral elements and urea. This preparation containing, among other things, over 55% of urea, 4% of P, 3.5% of Ca and 3.7% of Na. The preparation was tested in 1983 on 48 young bulls of the lowland black-and-white breed divided into 3 groups, by 16 animals in each group. Animals were fed individually. On the basis of results obtained in the tests the following conclusions can be drawn: - application of the new urea-mineral preparation gave similar productive results as application of the „Wałczan” preparation, - utilization of N-urea from the new preparation was not better than that of „Wałczan” and crystalline urea, - the advantage of the new urea-mineral preparation is that it can be produced almost exclusively from home raw materials. However, further feeding experiments, which would enable to get more detailed information about the value of this preparation, should be carried out

Aberrant repair of etheno-DNA adducts in leukocytes and colon tissue of colon cancer patients

International audienceTo assess the role of lipid peroxidation-induced DNA damage and repair in colon carcinogenesis, the excision rates and levels of 1,N-6-etheno-2'-deoxyadenosine (epsilon dA), 3,N-4-etheno-2'-deoxycytidine (epsilon dC), and 1,N-2-etheno-2'-deoxyguanosine (1,N-2-epsilon dG) were analyzed in polymorphic blood leukocytes (PBL) and resected colon tissues of 54 colorectal carcinoma (CRC) patients and PBL of 56 healthy individuals. In PBL the excision rates of 1,N-6-ethenoadenine (epsilon Ade) and 3,N-4-ethenocytosine (epsilon Cyt), measured by the nicking of oligodeoxynucleotide duplexes with single lesions, and unexpectedly also the levels of epsilon dA and 1,N-2-epsilon dG, measured by LC/MS/MS, were lower in CRC patients than in controls. In contrast the mRNA levels of repair enzymes, alkylpurine- and thymine-DNA glycosylases and abasic site endonuclease (APE1), were higher in PBL of CRC patients than in those of controls, as measured by QPCR. In the target colon tissues epsilon Ade and epsilon Cyt excision rates were higher, whereas the epsilon dA and epsilon dC levels in DNA, measured by P-32-postlabeling, were lower in tumor than in adjacent colon tissue, although a higher mRNA level was observed only for APE1. This suggests that during the onset of carcinogenesis, etheno adduct repair in the colon seems to be under a complex transcriptional and posttranscriptional control, whereby deregulation may act as a driving force for malignancy

Two phase 3 studies of alicalorsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease

C